Comparing Efficacy of Cariprazine vs Amisulpride as add-on treatment options for Negative Symptoms of Schizophrenia

Phase 4

• Conditions: Health Condition 1: F205- Residual schizophrenia

• Registration Number: CTRI/2023/09/058092
• Lead Sponsor: Debibrata Acharya

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1.18-65 Years old

2.All patients irrespective of Gender

3.ICD 10 Diagnosis of Schizophrenia

4.Clinically Stable defined as total score change =20 % on two sequential ratings (every two weeks for a month) on the positive and negative syndrome scale (PANSS)

5.Patients providing valid informed consent

Exclusion Criteria

1.Patients with other psychiatric disorders (e.g., schizoaffective disorder, bipolar disorder, severe axis II disorders)

2.Patients with Treatment resistance (i.e., poor response to =2 antipsychotics of adequate dose and duration during the past 2 years)

3.Patients with any substance abuse (except nicotine) within 3 months of the study or Patients with substance (with the exception of nicotine) dependence within the last 6 months.

4.Patients with suicide risk (based on the psychiatric interview or the Columbia-Suicide Severity Rating Scale [C-SSRS])

5.Patient under treatment of clozapine

6. Have received electroconvulsive therapy (ECT) in the past 6 months

7.Active Depressive Symptoms; CDSS score >6

8.Patients with Intellectual Developmental Disorder (IDD)

9.Serious medical or neurological illness or seizures

10.History of neurosurgery or head trauma

Study & Design

• Study Type: Interventional
• Study Design: Not specified